US2016272589A1PendingUtilityA1
Dual mechanism inhibitors for the treatment of disease
Est. expiryMay 1, 2029(~2.8 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 9/10A61P 9/00A61P 35/00A61P 43/00A61P 3/04A61P 29/00A61P 27/06A61P 27/00A61P 27/04A61P 27/02A61P 1/16A61P 11/00A61P 13/12A61P 19/08A61P 13/10A61P 17/14A61P 1/04A61P 19/02A61P 11/02A61P 15/18A61P 1/00A61P 1/18A61P 17/00C07D 217/02C07D 413/12C07D 217/24C07D 333/38C07D 417/12C07C 237/42C07D 405/12C07D 217/00C07D 217/04C07C 2601/08C07D 401/12C07C 237/20C07C 2601/14C07D 217/22C07D 333/40C07D 409/12
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Claims
exact text as granted — not AI-modified1 .- 39 . (canceled)
40 . A compound according to the Formula:
and salts thereof,
wherein R 1 , R 2 , and R 3 are independently hydrogen or C 1 -C 4 alkyl;
wherein A is C 1 -C 4 alkyl, or forms a ring structure with R 1 , R 2 , or R 3 ;
wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 22 alkyl, C 1 -C 22 alkyl aryl, C 1 -C 22 alkyl heteroaryl, C 2 -C 22 alkenyl, C 2 -C 22 alkynyl, C 1 -C 22 carbonyl, C 1 -C 22 carbonylamino, C 1 -C 22 alkoxy, C 1 -C 22 sulfonyl, C 1 -C 22 sulfonylamino, C 1 -C 22 thioalkyl, or C 1 -C 22 carboxyl;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C r C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein the double circle
indicates an aromatic or heteroaromatic ring; and
wherein each Z is independently a bond.
41 . A compound according to claim 40 , wherein R 1 is hydrogen or C 1 -C 4 alkyl; B is C 1 -C 22 carbonyl; X 1 , X 2 , and X 3 are hydrogen; the double circle
indicates an aromatic or heteroaromatic ring; and Z is a bond, C 1 -C 4 alkyl, C 1 -C 4 heteroalkyl, or an O atom.
42 . A compound according to claim 40 , wherein X 1 , X 2 and X 3 are each hydrogen.
43 . A compound according to claim 40 , wherein R 1 and R 2 are independently hydrogen or methyl.
44 . A compound according to claim 40 , wherein R 3 is C 1 -C 4 alkyl.
45 . A compound according to claim 40 , wherein the double circle
is a phenyl ring.
46 . A compound according to claim 40 , wherein R 1 and R 2 are hydrogen or methyl; R 3 is hydrogen; the double circle
is a phenyl ring; X 1 , X 2 , and X 3 are hydrogen; A is —CH 2 —; and B is C 1 -C 22 carbonyl.
47 . A compound according to claim 46 , wherein B is —CH 2 C(O)R and R is aryl or alkyl.
48 . A compound according to claim 47 , wherein R is phenyl.
49 . A compound according to claim 47 , wherein R is C 1-4 alkyl.
50 . A compound according to Formula IV:
and salts thereof,
wherein R 1 and R 2 are independently hydrogen or C 1 -C 4 alkyl;
wherein R 3 is a hydrogen or C 1 -C 4 alkyl;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein B is hydrogen, C 1 -C 18 alkyl, C 1 -C 18 alkyl aryl, C 1 -C 18 alkyl heteroaryl, C 1 -C 18 carbonyl, C 1 -C 18 carbonylamino, C 1 -C 18 sulfonyl, C 1 -C 18 sulfonylamino, or C 1 -C 18 carboxyl; and
wherein Z is a bond.
51 . A compound according to claim 50 , wherein R 1 and R 2 are hydrogen or methyl; X 1 , X 2 , and X 3 are hydrogen; and B is C 1-18 carbonyl.
52 . A compound according to claim 51 , wherein B is —CH 2 C(O)R and R is aryl or alkyl.
53 . A compound according to claim 52 , wherein R is phenyl.
54 . A compound according to claim 52 , wherein R is C 1-4 alkyl.
55 . A compound selected from the group consisting of:
56 . A compound selected from the group consisting of:
Example
X
R
279
O
Ph
280
OH
Ph
281
O
-4-MeOPh
282
O
-3-MeOPh.
57 . A compound selected from the group consisting of:
Example
X
R1
R2
283
O
-2-F—Ph
Me
284
O
-2,4 diCl—Ph
H
285
O
-3-MePh
H
286
OH
-4-MeOPh
H
287
OH
-2-MeOPh
H
288
OH
-3-MePh
Me.
58 . A pharmaceutical composition comprising a compound according to claim 40 and a pharmaceutically acceptable carrier.
59 . A method for treating a disease in a subject comprising administering to a subject an effective amount of a compound according to claim 40 ; wherein the disease comprises eye disease.
60 . The method of claim 59 , wherein the eye disease comprises glaucoma or neurodegenerative eye disease.
61 . A method of modulating kinase activity comprising contacting a cell with an compound according to claim 40 in an amount effective to modulate kinase activity.
62 . The method of claim 61 , wherein the cell is in a subject.
63 . A method of reducing intraocular pressure comprising contacting a cell with a compound according to claim 40 in an amount effective to reduce intraocular pressure.
64 . The method of claim 63 , wherein the cell is in a subject.Join the waitlist — get patent alerts
Track US2016272589A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.